| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5677331 | NOVARTIS | Antimalarial compositions |
Oct, 2014
(9 years ago) | |
Coartem is owned by Novartis.
Coartem contains Artemether; Lumefantrine.
Coartem has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Coartem are:
- US5677331
Coartem was authorised for market use on 07 April, 2009.
Coartem is available in tablet;oral dosage forms.
Coartem can be used as treatment of acute, uncomplicated malaria infection due to plasmodium falciparum in patients of 5kg bodyweight and above.
Drug patent challenges can be filed against Coartem from 07 April, 2013.
The generics of Coartem are possible to be released after 07 April, 2016.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2014 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2016 |
Drugs and Companies using ARTEMETHER; LUMEFANTRINE ingredient
NCE-1 date: 07 April, 2013
Market Authorisation Date: 07 April, 2009
Treatment: Treatment of acute, uncomplicated malaria infection due to plasmodium falciparum in patients of 5kg bodyweight and above
Dosage: TABLET;ORAL
COARTEM family patents
